The global nucleic acid isolation and purification market is projected to reach USD 9.4 billion by 2028 from USD 6.4 billion in 2023, at a CAGR of 8.1% during the forecast period. The growth of this market is majorly driven by factors such as increasing R&D activities as well as technological advancements. Technological advancements such as higher throughput and purification automation are generating interest not only in research laboratories but also in pharmaceutical and biotechnology companies. Over the years, the nucleic acid isolation and purification market has witnessed significant technological developments—from labor-intensive reagent-based isolation techniques to magnetic bead-based technologies and fully automated systems—for the isolation and purification of nucleic acids. The emerging economies are expected to offer a wide range of growth opportunities for players in the market. On the other hand, the high cost of automated instruments is expected to hinder the growth to a certain extent.
The global nucleic acid isolation and purification market is competitive, with large, medium-sized, and small market players. The global nucleic acid isolation and purification market was dominated by top players such as Thermo Fisher Scientific Inc. (US), QIAGEN (Germany), Merck KGaA (Germany), and F. Hoffmann- La Roche Ltd. (Switzerland).
To know about the assumptions considered for the study download the pdf brochure
THERMO FISHER SCIENTIFIC INC.
In 2022, Thermo Fisher Scientific was a major player in the nucleic acid isolation and purification market. This global company is known for its comprehensive range of analytical instruments, laboratory equipment, software, consumables, reagents, and services designed for the nucleic acid isolation and purification sector. Thermo Fisher Scientific has a substantial worldwide presence. With this extensive global reach, the company remains committed to advancing product and technological innovations in the nucleic acid isolation and purification market, resulting in a significant increase in its overall revenue. It focuses on acquiring new consumers through expansions, partnerships, and collaborations in emerging markets like China, India, and South Korea. In the last three years, the company has also focused on bringing technologically advanced instruments to the market to enhance its research capabilities. The company can also explore strategic agreements and partnerships, for instance, in May 2022, Thermo Fisher partnered with the Qatar Genome Program (QGP), a member of the Qatar Foundation (QF), to accelerate genomic research and clinical applications of predictive genomics in Qatar.
QIAGEN
QIAGEN is one of the key providers of molecular diagnostic solutions, innovative technologies, and products for preanalytical sample preparation, making it one of the key competitors in the market. It offers a wide array of isolation and purification kits for RNA and DNA. The company has an elaborate service portfolio and a strong product profile in nucleic acid purification. The company has a well-established brand name for the services market. It has a wide geographical presence with direct distribution channels as well as manufacturing and research & development facilities across the globe. This allows the company to reach out to a fragmented customer base. QIAGEN aims to provide quality services with high levels of safety in all operating markets. The company focuses on acquisitions and expansions to enhance its product portfolio and market share. It also aims to introduce technologically advanced products to cater to changing customer needs. With a strong life science product portfolio and improving life science services, the company is likely to grow in the nucleic acid isolation and purification market.
F. HOFFMANN-LA ROCHE LTD.
Roche Diagnostics is a major player in the nucleic acid isolation and purification market, driven by substantial investments in research and development. To stay competitive, the company pursues inorganic growth strategies like agreements and acquisitions, expanding its product range. Roche Diagnostics is committed to introducing user-friendly, integrated products, further strengthening its market presence. They offer a wide array of RNA and DNA isolation and purification kits, alongside a comprehensive service portfolio and a strong product lineup in the nucleic acid sector. The company also has a well-established brand name in the market. It has a wide geographical presence with direct distribution channels as well as manufacturing and research & development facilities across the globe.
MERCK KGAA
Merck KGaA has established itself as a major player in the nucleic acid isolation and purification market, primarily due to its strong product portfolio. Researchers often choose Merck instruments for their experiments because of the consistent quality and results they provide. The company's strategy for growth is centered on internal research and development, with a substantial investment of USD 2.66 billion in R&D in 2022. With its robust R&D capabilities and expanding global presence, Merck is expected to maintain its leading position in the market. By focusing on both in-house research and external partnerships, Merck enhances research efficiency and product portfolio expansion.
Related Reports:
Nucleic Acid Isolation and Purification Market by Product (Kits, Reagents, Instruments), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, mRNA), Application (Diagnostics, Personalized Medicine), End User (CROs) - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE